Files and links (1)
Published, Version of Record (VoR)CC BY-NC V4.0, Open
Journal article
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Advances in therapy, v 40(10), pp 4493-4503
01 Oct 2023
PMID: 37542646
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction
This study evaluated 12 months adherence and persistence among Janus kinase inhibitors (upadacitinib, baricitinib, tofacitinib) and adalimumab, a tumor necrosis factor inhibitor (TNFi), in patients with rheumatoid arthritis (RA).
Methods
This retrospective analysis used administrative claims data from the Merative & TRADE; MarketScan(& REG;) Research Databases (2018-2022). Eligible adults had & GE; 1 RA diagnosis before the index date, & GE; 1 pharmacy claim for index medication, and & GE; 12 months of continuous insurance enrollment pre- and post-index. Adherence to treatment [defined as proportion of days covered (PDC) & GE; 80%], risk of treatment discontinuation, and mean time to discontinuation were assessed during the 12 months follow-up. Adjusted odds ratios (aOR), adjusted hazard ratios (aHR), and 95% confidence intervals (CI) were reported.
Results
In total, 6317 patients were included (683 upadacitinib, 3732 adalimumab, 132 baricitinib, 1770 tofacitinib). Compared with upadacitinib, patients initiating adalimumab [aOR (95% CI): 0.82 (0.69, 0.96)], baricitinib [0.46 (0.31, 0.68)], and tofacitinib [0.74 (0.62, 0.88)] were significantly less likely to achieve PDC & GE; 80%. Risk of treatment discontinuation was significantly higher in patients treated with adalimumab [aHR (95% CI): 1.14 (1.01, 1.29)], baricitinib [1.48 (1.16, 1.90)], and tofacitinib [1.22 (1.07, 1.38)] compared with upadacitinib. Mean time to discontinuation was 256 (upadacitinib), 249 (adalimumab), 221 (baricitinib), and 239 (tofacitinib) days. Similar results were observed in patients with prior TNFi use.
Conclusions
Patients with RA, regardless of recent TNFi experience, initiating upadacitinib were significantly more likely to be adherent and less likely to discontinue therapy compared to adalimumab, baricitinib, and tofacitinib in the first 12 months of treatment.
Metrics
Details
- Title
- One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
- Creators
- Martin Bergman - Drexel University, Medicine (Graduate)Naijun Chen - AbbVie Inc, 26525 N Riverwoods Blvd, N Chicago, IL 60045 USARichard Thielen - AbbViePatrick Zueger - AbbVie Inc, 26525 N Riverwoods Blvd, N Chicago, IL 60045 USA
- Publication Details
- Advances in therapy, v 40(10), pp 4493-4503
- Publisher
- Springer Nature
- Number of pages
- 11
- Grant note
- AbbVie
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:001042787000001
- Scopus ID
- 2-s2.0-85166912624
- Other Identifier
- 991021861175904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy